Journal of Cutaneous Immunology and Allergy最新文献

{"title":"A case of disseminated extranodal Rosai–Dorfman disease diagnosed by skin manifestations","authors":"Shintaro Saito MD,&nbsp;Akihiko Uchiyama MD, PhD,&nbsp;Yayoi Shibusawa MD, PhD,&nbsp;Sei-ichiro Motegi MD, PhD","doi":"10.1002/cia2.12286","DOIUrl":"10.1002/cia2.12286","url":null,"abstract":"<p>Rosai–Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis that was first described as sinus histiocytosis with massive lymphadenopathy by Rosai and Dorfman in 1969. While classical/nodal RDD is typical, extranodal involvement is seen in up to 43% of all cases, with 23% showing only extranodal lesions. Here, we present a case of disseminated extranodal RDD, where the initial symptoms were cutaneous manifestations.</p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"105-107"},"PeriodicalIF":1.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12286","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46485252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cold-induced anaphylactic shock during playing in a thigh-deep river: A pediatric case","authors":"Ayumi Sakai MD,&nbsp;Naoko Inomata MD, PhD,&nbsp;Kohei Yamakawa MD,&nbsp;Yukie Yamaguchi MD, PhD","doi":"10.1002/cia2.12285","DOIUrl":"10.1002/cia2.12285","url":null,"abstract":"<p>We report a pediatric patient with acquired cold urticaria who developed a systemic reaction triggered by localized cold exposure. By determining the critical threshold temperature using TempTest®, we were able to minimize restriction in activities.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"108-109"},"PeriodicalIF":1.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12285","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44906283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult-onset Still's disease following mRNA-1273 Moderna COVID-19 vaccination: A case report","authors":"Masahiro Iwata MD,&nbsp;Tatsuya Ogawa MD, PhD,&nbsp;Keisuke Anju MD,&nbsp;Naoko Okiyama MD, PhD,&nbsp;Toshifumi Nomura MD, PhD","doi":"10.1002/cia2.12281","DOIUrl":"10.1002/cia2.12281","url":null,"abstract":"<p>A 57-year-old woman who was inoculated with the second dose of the mRNA-1273 Moderna COVID-19 vaccine and then developed adult-onset still’s disease as a result.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 2","pages":"66-67"},"PeriodicalIF":1.0,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12281","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45591410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris","authors":"Kazuki Yatsuzuka MD,&nbsp;Masamoto Murakami MD, PhD","doi":"10.1002/cia2.12284","DOIUrl":"10.1002/cia2.12284","url":null,"abstract":"<p>This was the first case report in which an in-class IL-23 p19 inhibitor was switched (from guselkumab to tildrakizumab) during psoriasis vulgaris treatment. Four months after the switch, genital lesions, which were the patient's most significant complaint, improved with no subsequent worsening. We believe that our case will aid physicians who work in this problematic clinical setting.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"98-99"},"PeriodicalIF":1.0,"publicationDate":"2022-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12284","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48477591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis","authors":"Kanako Kita MD,&nbsp;Yasutomo Imai MD, PhD,&nbsp;Makoto Nagai MD, PhD,&nbsp;Masaru Natsuaki MD, PhD,&nbsp;Nobuo Kanazawa MD, PhD","doi":"10.1002/cia2.12282","DOIUrl":"10.1002/cia2.12282","url":null,"abstract":"<p>Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"100-101"},"PeriodicalIF":1.0,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12282","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44774205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relapsing erythema nodosum-like eruption in a patient with granulomatosis with polyangiitis","authors":"Satomi Imamoto MD,&nbsp;Chie Miyabe MD, PhD,&nbsp;Ryujin Miyata MD,&nbsp;Yasuko Fukuya MD, PhD,&nbsp;Naoko Ishiguro MD, PhD","doi":"10.1002/cia2.12283","DOIUrl":"10.1002/cia2.12283","url":null,"abstract":"<p>We report a rare case of granulomatosis with polyangiitis (GPA) who presented with relapsing erythema nodosum (EN)-like eruption as a solo vasculitis-associated cutaneous manifestation. We suggest that EN-like eruption alone can be a cutaneous symptom of GPA if subcutaneous medium-sized vessels are exclusively affected. \u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"102-104"},"PeriodicalIF":1.0,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46036935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Criteria for Accepting or Rejecting Cord Blood Units","authors":"Khalid Kazim","doi":"10.37191/mapsci-2582-6549-3(2)-037","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-3(2)-037","url":null,"abstract":"Rare hematopoietic stem cell populations are responsible for the transplantation engraftment process. Umbilical cord blood (UCB) is usually processed to the total nucleated cell (TNC), but not to the mononuclear cell (MNC) fraction. TNC counts are used to determine UCB unit storage, release for transplantation and correlation with time to engraftment [1]. It has been mentioned in the literature that there are several factors that affect harvesting of cord blood stem cells [2]. It was set to analyze the relationship between fetal weight and other factors that led to rejection of CBUs brought to DCRC from public and private donations. In this retrospective study, 375 donations of CBUs from January 2018 to October 2018 at DCRC were recorded. From literature, factors that are usually involved in rejection of CBUs were recorded and analyzed to mark the leading cause of rejection criteria. In this study, it showed that results did not find infants’ birth weight or mother’s age to have any value in rejection. Other factors’ results will be discussed.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"48 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85919744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional and Cellular Immunotherapy (FCIT) Concept","authors":"Khalid Kazim","doi":"10.37191/mapsci-2582-6549-3(2)-034","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-3(2)-034","url":null,"abstract":"Inflammation is the process by which the immune system recognizes and removes environmental factors, and begins the healing process. Inflammation can be either acute or chronic. However, the cause of many chronic inflammatory conditions is poorly understood. Chronic inflammatory responses are an ongoing process as long as the environmental factor is present. Sometimes, the response makes the body attack itself.\u0000\u0000In this paper a closer look at finding out the causes of chronic inflammations, how to treat them on an individual basis, how to reverse the disease early on, and how to repair damages that the inflammation has caused.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"43 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83486955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2-year experience","authors":"Chisako Fujiwara MD, PhD,&nbsp;Akihiko Uchiyama MD, PhD,&nbsp;Yuta Inoue MD,&nbsp;Mai Ishikawa MD,&nbsp;Sei-ichiro Motegi MD, PhD","doi":"10.1002/cia2.12280","DOIUrl":"10.1002/cia2.12280","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Dupilumab has been deemed highly effective for atopic dermatitis (AD). However, there have been no reports performing a combination analysis with hematological data and improvement rates pertaining to the continued use of dupilumab for up to 2 years in real world. In this study, we evaluated the effectiveness and safety of using dupilumab for up to 2 years in 9 patients with AD at our hospital.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty-six patients with moderate-to-severe AD treated by dupilumab, and 9 of them treated for 2 years. Changes in the severity scoring, pruritus numerical rating scale (NRS), patient-oriented eczema measure (POEM), serum levels of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), eosinophils, and lactate dehydrogenase (LDH) at Week 0, 2, 4, 16, 48, 72, and 96 of those patients were investigated, and we studied features of the patients who had any adverse events (AEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Investigator’s global assessment (IGA), eczema area and severity index (EASI), body surface area (BSA), NRS, POEM, and serum levels of LDH were significantly decreased from Week 4 onwards to Week 96 compared with baseline condition. Serum levels of TARC and LDH were significantly decreased from Week 4 onwards to Week 96. Regarding 9 patients who were treated with dupilumab for up to 2 years, serum levels of TARC and eosinophils decreased without statistical significance. The serum levels of IgE significantly decreased at Week 72, 96 compared with the baseline. Regarding as AEs, ocular symptoms were the most frequently observed (15/36, 41.2%), and there were no cases of discontinuation due to AEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Treatment with dupilumab was well tolerated and showed improvements in AD for at least 2 years.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"6 3","pages":"88-93"},"PeriodicalIF":1.0,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cia2.12280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42107265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Causes ME/CFS: The Role of the Dysfunctional Immune System and Viral Infections","authors":"A. Bansal","doi":"10.37191/mapsci-2582-6549-3(2)-033","DOIUrl":"https://doi.org/10.37191/mapsci-2582-6549-3(2)-033","url":null,"abstract":"Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remains an enigmatic highly disabling and complex long-term condition with a wide range of aetiologies and symptoms. A viral onset is commonly mentioned by patients and several bodily systems are ultimately disturbed. The parallel with long-covid is clear. However, immune dysregulation with impaired NK cell dysfunction and tendency to novel autoimmunity have been frequently reported. These may contribute to reactivation of previous acquired viruses/retrovirusesaccompanied by impaired endocrine regulation and mitochondrial energy generation. The unpredictable nature of seemingly unconnected and diverse symptoms that are poorly responsive to several allopathic and alternative therapies then contributes to an escalation of the illness with secondary dysfunction of multiple other systems. Treatment of established ME/CFS is therefore difficult and requires multi-specialty input addressing each of the areas affected by the illness.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"61 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2022-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90592103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}